Letrovena

Letrozole, the active ingredient in Letrovena, is an aromatase inhibitor presented as a tablet (strength not specified) for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen‑driven tumor growth and improving disease‑free survival outcomes.

GNH USA supplies Letrovena as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and clinical research sites worldwide, adhering to stringent quality standards, regulatory compliance and providing reliable sourcing for global therapeutic programs across multiple continents.

Letrovena (letrozole) acts on estrogen synthesis pathways and is indicated for several breast‑cancer treatment settings.

- Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer: reduces risk of recurrence after surgery. - Neoadjuvant therapy before surgery: may shrink tumor size to facilitate breast‑conserving surgery. - Metastatic hormone receptor‑positive breast cancer: slows disease progression and prolongs survival. - Extended adjuvant therapy after initial treatment: maintains disease‑free status.

Common Side Effects: - Hot flashes: transient episodes of warmth and sweating. - Joint and muscle pain: aching discomfort in limbs. - Nausea: mild to moderate upset stomach. - Fatigue: persistent tiredness. - Headache: occasional mild pain.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Deep vein thrombosis or pulmonary embolism: swelling, chest pain, shortness of breath. - Bone fracture: increased risk due to reduced estrogen. - Severe allergic reaction: rash, swelling, difficulty breathing. - QT interval prolongation: cardiac rhythm disturbance.

Patients should be monitored for specific safety considerations before and during therapy. - Monitor bone health: assess calcium and vitamin D status regularly. - Assess liver function: perform periodic liver‑function tests. - Evaluate cardiovascular risk: watch for signs of thromboembolic events. - Avoid use in premenopausal women: not indicated for this population. - Pregnancy warning: contraindicated in pregnancy; ensure effective contraception. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Potential drug interactions may affect letrozole efficacy or safety.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: reduces letrozole effectiveness. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma concentrations. - Tamoxifen: antagonistic effect on estrogen modulation.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - CYP2C19 inhibitors (e.g., fluconazole): can raise letrozole levels modestly. - SSRIs with QT‑prolonging potential: monitor cardiac rhythm.